In vivo activities of recombinant divercin V41 and its structural variants against Listeria monocytogenes.
Recombinant divercin RV41 (DvnRV41) and its structural variants were used in this study to assess their antilisterial activities in vivo in mice challenged intravenously with Listeria monocytogenes EGDe. Treatment with DvnRV41 before and after infection permitted a conclusion as to the capacities of this peptide to retain activity and reduce growth of L. monocytogenes EGDe. Moreover, the use of structural variants for the first time in vivo and the reductions of their activities confirmed the importance of certain amino acids in antilisterial activity.
UMR INRA SECALIM 1014 ENITIAA/ENVN, Rue de la Géraudière, BP 82225, 44322 Nantes Cedex 3, France.
Jitka
J
Rihakova
Jean-Michel
JM
Cappelier
Isabelle
I
Hue
Katerina
K
Demnerova
Michel
M
Fédérighi
Hervé
H
Prévost
Djamel
D
Drider
D000596:Amino Acids / Q000737:chemistry; D000818:Animals; D000900:Anti-Bacterial Agents; D001430:Bacteriocins / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D003470:Culture Media; D005260:Female; D008089:Listeria monocytogenes / Q000187:drug effects* / Q000254:growth & development; D008088:Listeriosis / Q000188:drug therapy* / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D011994:Recombinant Proteins; D013154:Spleen / Q000382:microbiology
D000596:Amino Acids; D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D003470:Culture Media; D010455:Peptides; D011994:Recombinant Proteins; C116372:divercin V41